TD Cowen analyst Dan Brennan initiated coverage of Tempus AI with a Buy rating and $50 price target. The analyst believes Tempus is the largest oncology diagnostics company for comprehensive genomic profiling by test volumes with leading growth in a large total addressable market. The firm sees 32% annual growth over the next three years and a “scalable model” enabling free cash flow by 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Largest borrow rate increases among liquid names
- CMS awards Tempus AI with ADLT status for xT CDx test
- Tempus AI receives 510(k) clearance for Tempus ECG-AF
- Tempus AI, United Therapeutics collaborate to study use of AI to detect PH risk
- Tempus AI receives 510(k) Premarket Notification for Tempus ECG-AF